JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

Home・Akciju saraksts・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

49.3 -0.28

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

48.74

Max

50.06

Galvenie mērījumi
By Trading Economics
Ienākumi	6.6M -39M
Pārdošana	19M 212M
P/E Sektora vidējais	48.435 60.328
EPS	0.882
Peļņas marža	-18.221
Darbinieki	778
EBITDA	127M 90M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+26.95% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	45M 3B
Iepriekšējā atvēršanas cena	49.58
Iepriekšējā slēgšanas cena	49.3

Ziņu noskaņojums

By Acuity

50%

157 / 348 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

31.35 / 32.36 Atbalsts un pretestība

Supernus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 27. apr. 23:15 UTC

Galvenie ziņu notikumi

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

2026. g. 27. apr. 23:08 UTC

Peļņas

Galvenie tirgus virzītāji

LendingClub Shares Gain on 1Q Profit, Revenue Beat

2026. g. 27. apr. 23:58 UTC

Peļņas

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

2026. g. 27. apr. 23:58 UTC

Peļņas

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

2026. g. 27. apr. 23:56 UTC

Peļņas

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

2026. g. 27. apr. 23:56 UTC

Peļņas

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

2026. g. 27. apr. 23:48 UTC

Tirgus saruna

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

2026. g. 27. apr. 23:42 UTC

Tirgus saruna

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

2026. g. 27. apr. 23:34 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

2026. g. 27. apr. 23:30 UTC

Tirgus saruna

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

2026. g. 27. apr. 23:08 UTC

Tirgus saruna

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

2026. g. 27. apr. 23:02 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 27. apr. 23:02 UTC

Tirgus saruna

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

2026. g. 27. apr. 22:42 UTC

Tirgus saruna

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

2026. g. 27. apr. 22:10 UTC

Peļņas

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

2026. g. 27. apr. 22:09 UTC

Peļņas

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

2026. g. 27. apr. 22:09 UTC

Peļņas

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

2026. g. 27. apr. 22:09 UTC

Peļņas

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

2026. g. 27. apr. 21:56 UTC

Peļņas

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

2026. g. 27. apr. 21:55 UTC

Peļņas

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

2026. g. 27. apr. 21:55 UTC

Peļņas

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

2026. g. 27. apr. 21:44 UTC

Peļņas

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

2026. g. 27. apr. 21:43 UTC

Peļņas

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

2026. g. 27. apr. 21:41 UTC

Peļņas

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

2026. g. 27. apr. 21:41 UTC

Peļņas

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

2026. g. 27. apr. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 27. apr. 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 27. apr. 20:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 27. apr. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 27. apr. 20:39 UTC

Peļņas

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Salīdzinājums

Cenas izmaiņa

Supernus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

26.95% augšup

Prognoze 12 mēnešiem

Vidējais 63.17 USD 26.95%

Augstākais 66 USD

Zemākais 55 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

31.35 / 32.36Atbalsts un pretestība

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

157 / 348 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.